Metabolic Syndrome Associated with Increased Blood Clot Recurrence Risk
|
By LabMedica International staff writers Posted on 21 Jan 2020 |

Image: Schematic diagram of deep vein thrombosis (DVT) that is associated with metabolic syndrome (Photo courtesy of MediConnect).
People with metabolic syndrome which are a set of conditions including obesity, impaired glucose metabolism, elevated levels of fats and cholesterol in the blood, and high blood pressure, are more likely to experience recurrent blood clots.
Among patients diagnosed with a type of blood clot known as deep vein thrombosis (DVT), those who also had markers of metabolic syndrome were more likely to experience another venous thromboembolism (VTE) event. Furthermore, as the number of metabolic syndrome conditions that the patients exhibited increased, so too did their likelihood of experiencing VTE recurrence.
Medical scientists from the Indiana University School of Medicine (Indianapolis, IN, USA;) used a statewide database analyze 151,054 patients diagnosed with DVT from 2004 to 2017. They examined four metabolic syndrome components: hypertension (high blood pressure), hyperlipidemia (high levels of fat in the blood), diabetes (high levels of sugar in the blood), and obesity.
The investigators found that 68% of DVT patients had also been diagnosed with at least one of those conditions. The presence of comorbid metabolic syndrome was associated with a 17% increase in overall likelihood of blood clot recurrence. The study also showed that the risk of subsequent blood clots increased with each additional metabolic syndrome component: patients without any of the four markers for metabolic syndrome had a VTE recurrence rate of 7%. Those patients who had been diagnosed with one component of metabolic syndrome were found to be at a 14% risk of additional blood clots, followed by 21% risk among patients with two components, 30% for those with three components, and 37% for those diagnosed with all four components.
Another interesting finding involved the role of anticoagulant therapy. The scientist found that although patients who had been diagnosed with both DVT and metabolic syndrome had higher documented rates and duration of anticoagulant use, the link between metabolic syndrome and increased risk of VTE recurrence persisted. This suggests that metabolic syndrome may have an even greater effect on VTE risk than observed, and that the effect may have been minimized due to anticoagulant therapy.
Lauren K. Stewart, MD, an associate professor and first author of the study, said, “Our aim was to improve understanding of the effect of metabolic syndrome on blood clot recurrence. If patients have VTE recurrence, their quality of life drops, and it drops a lot. We wanted to investigate possible comorbidities and factors that affect recurrence so we could stimulate the search for new potential treatments.” The study was published on January 9, 2020 in the journal Blood Advances
Related Links:
Indiana University School of Medicine
Among patients diagnosed with a type of blood clot known as deep vein thrombosis (DVT), those who also had markers of metabolic syndrome were more likely to experience another venous thromboembolism (VTE) event. Furthermore, as the number of metabolic syndrome conditions that the patients exhibited increased, so too did their likelihood of experiencing VTE recurrence.
Medical scientists from the Indiana University School of Medicine (Indianapolis, IN, USA;) used a statewide database analyze 151,054 patients diagnosed with DVT from 2004 to 2017. They examined four metabolic syndrome components: hypertension (high blood pressure), hyperlipidemia (high levels of fat in the blood), diabetes (high levels of sugar in the blood), and obesity.
The investigators found that 68% of DVT patients had also been diagnosed with at least one of those conditions. The presence of comorbid metabolic syndrome was associated with a 17% increase in overall likelihood of blood clot recurrence. The study also showed that the risk of subsequent blood clots increased with each additional metabolic syndrome component: patients without any of the four markers for metabolic syndrome had a VTE recurrence rate of 7%. Those patients who had been diagnosed with one component of metabolic syndrome were found to be at a 14% risk of additional blood clots, followed by 21% risk among patients with two components, 30% for those with three components, and 37% for those diagnosed with all four components.
Another interesting finding involved the role of anticoagulant therapy. The scientist found that although patients who had been diagnosed with both DVT and metabolic syndrome had higher documented rates and duration of anticoagulant use, the link between metabolic syndrome and increased risk of VTE recurrence persisted. This suggests that metabolic syndrome may have an even greater effect on VTE risk than observed, and that the effect may have been minimized due to anticoagulant therapy.
Lauren K. Stewart, MD, an associate professor and first author of the study, said, “Our aim was to improve understanding of the effect of metabolic syndrome on blood clot recurrence. If patients have VTE recurrence, their quality of life drops, and it drops a lot. We wanted to investigate possible comorbidities and factors that affect recurrence so we could stimulate the search for new potential treatments.” The study was published on January 9, 2020 in the journal Blood Advances
Related Links:
Indiana University School of Medicine
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







